Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh Ph Patel sold 7,278 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the sale, the chief executive officer owned 522,968 shares in the company, valued at approximately $75,359,688.80. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Stock Up 2.1%
Shares of PTGX stock opened at $148.18 on Friday. The business has a 50 day moving average of $143.14 and a two-hundred day moving average of $116.95. Protagonist Therapeutics, Inc. has a 52 week low of $57.90 and a 52 week high of $160.81. The company has a market cap of $9.59 billion, a P/E ratio of 143.87 and a beta of 1.80.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.27 by $0.02. The company had revenue of $213.47 million during the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm’s revenue for the quarter was up 3746.8% compared to the same quarter last year. Analysts expect that Protagonist Therapeutics, Inc. will post 4.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on PTGX. Truist Financial upped their price objective on Protagonist Therapeutics from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Johnson Rice set a $165.00 price objective on shares of Protagonist Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 22nd. Citigroup boosted their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Finally, BMO Capital Markets raised their price target on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $147.13.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a biopharmaceutical company focused on developing peptide-based medicines for immune-mediated diseases and hematologic disorders. The company uses its peptide discovery and development platform to create therapies designed to selectively modulate disease-related biological pathways.
Protagonist’s pipeline has included icotrokinra (also known as JNJ-2113), an oral peptide that targets the interleukin-23 receptor and is being developed for inflammatory and immune-mediated conditions in collaboration with Johnson & Johnson.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
